Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Special Issue "Contemporary Treatment of Colorectal Cancer"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 2763

Share This Special Issue

Special Issue Editor

Dr. Michel Adamina

E-Mail Website
Guest Editor

Chief of Colorectal Surgery, Department of Surgery, Cantonal Hospital Winterthur, Brauerstrasse 15, Postfach 834, 8401 Winterthur, Switzerland
Interests: colorectal cancer; IBD; machine learning; colorectal surgery; leadership; medical education; pelvic floor; health economy; peritoneal cancer; cytoreductive surgery; HIPEC; PIPAC

Special Issue Information

Dear Colleagues,

Colorectal cancer is on the rise, with younger patients affected and a higher number of patients overall. Multimodal treatment has led to significant improvements in survival and quality of life with a majority of patients now amenable to a cure, including selected patients with peritoneal or solid organ metastases. Better screening, diagnostic accuracy and refined prognosis, as well as advanced therapeutic concepts, including multimodal neoadjuvant treatment, tailored surgery and multiple lines of adjuvant therapy, all contributed to the significant progress observed in clinical care and outcomes. The present Special Issue addresses the complexity of colorectal cancer and its contemporary management, with several topics highlighted: diagnostic and prognostic markers, cutting-edge imaging, total neoadjuvant and adjuvant therapy, state-of-the-art surgical approaches, including laparoscopic, robotic and transanal surgery, cytoreductive surgery and intraperitoneal chemotherapy, adjuvant chemo- and immunotherapy and best palliative care.

Dr. Michel Adamina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

colon cancer
rectum cancer
colorectal surgery
neoadjuvant treatment
adjuvant treatment
radiotherapy
chemotherapy
immunotherapy
minimally invasive surgery
laparoscopic surgery
transanal surgery, taTME, TAMIS
total mesorectal excision
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy, HIPEC
pressurized intraperitoneal chemotherapy, PIPAC

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Prognostic Significance of MRE11 Overexpression in Colorectal Cancer Patients

and

Cancers 2023, 15(9), 2438; https://doi.org/10.3390/cancers15092438 - 24 Apr 2023

Cited by 1 | Viewed by 836

Abstract

Meiotic recombination 11 (MRE11) plays a critical role in the DNA damage response and maintenance of genome stability and is associated with the prognosis for numerous malignancies. Here, we explored the clinicopathological significance and prognostic value of MRE11 expression in colorectal cancer (CRC), a leading cause of cancer-related deaths worldwide. Samples from 408 patients who underwent surgery for colon and rectal cancer between 2006 and 2011, including a sub-cohort of 127 (31%) patients treated with adjuvant therapy, were analyzed. In Kaplan–Meier survival analyses, we found that high MRE11 expression in the tumor center (TC) was significantly associated with poor disease-free survival (DFS; p = 0.045) and overall survival (OS; p = 0.039). Intriguingly, high MRE11 expression in the TC was also significantly correlated with reduced DFS (p = 0.005) and OS (p = 0.010) in the subgroup with right-sided primary CRC. In multivariate analyses, high MRE11 expression (hazard ratio [HR] = 1.697, 95% confidence interval [CI]: 1.034–2.785; p = 0.036) and lymphovascular/perineural invasion (LVI/PNI; HR = 1.922, 95% CI 1.122–3.293; p = 0.017) showed significant association with worse OS in patients with right-sided tumors but not those with left-sided tumors. Moreover, in patients with right-sided tumors, high MRE11 was associated with worse OS for those with lymph node involvement (p = 0.006) and LVI/PNI (p = 0.049). Collectively, our results suggest that MRE11 may serve as an independent prognostic marker in those with right-sided severe CRC, with clinical value in the management of these patients. Full article

(This article belongs to the Special Issue Contemporary Treatment of Colorectal Cancer)

► Show Figures

Figure 1

Open AccessArticle

Surgical Outcomes, Long-Term Recurrence Rate, and Resource Utilization in a Prospective Cohort of 165 Patients Treated by Transanal Total Mesorectal Excision for Distal Rectal Cancer

and

Cancers 2023, 15(4), 1190; https://doi.org/10.3390/cancers15041190 - 13 Feb 2023

Cited by 1 | Viewed by 841

Abstract

A transanal total mesorectal excision (taTME) is a smart alternative to a conventional TME. However, worrisome reports of a high recurrence and complications triggered a moratorium in a few countries. This study assessed the outcomes and resource utilization of a taTME. Consecutive patients with distal rectal cancer treated by a taTME were prospectively included. Outcomes were reported as the median and interquartile range (IQR). One hundred sixty-five patients (67% male and 33% female) with a tumor 7 cm (IQR 5–10) from the anal verge were followed for 50 months (IQR 32–79). The resection margins were threatened in 25% of the patients, while 75% of the patients received neoadjuvant radiochemotherapy. A good mesorectal dissection and clear margins were achieved in 96% of the specimens, and 27 lymph nodes (IQR 20–38) were harvested. Ninety-day major morbidity affected 36 patients (21.8%), including 12 with anastomotic leakages (7.2%). A recurrence occurred locally in 9 patients (5.4%), and 44 patients had a distant metastasis (26.7%). The five-year disease-free survival and overall survival were 67% and 90%, respectively. A multivariate analysis found a long operation and frailty predicted an anastomotic leak, while a positive distal margin and lymph nodes predicted a local recurrence and distant metastasis. A two-team taTME saved 102 min of operative time and EUR 1385 when compared to a one-team approach. Transanal total mesorectal excision produced sound surgical quality and excellent oncologic outcomes. Full article

(This article belongs to the Special Issue Contemporary Treatment of Colorectal Cancer)

Review

Jump to: Research

Open AccessReview

Alternative Splicing Events and Their Clinical Significance in Colorectal Cancer: Targeted Therapeutic Opportunities

Mosebo Armstrong Manabile

Rodney Hull

Richard Khanyile

Thulo Molefi

Botle Precious Damane

Nigel Patrick Mongan

David Owen Bates

and

Zodwa Dlamini

Cancers 2023, 15(15), 3999; https://doi.org/10.3390/cancers15153999 - 07 Aug 2023

Viewed by 654

Abstract

Colorectal cancer (CRC) ranks as one of the top causes of cancer mortality worldwide and its incidence is on the rise, particularly in low-middle-income countries (LMICs). There are several factors that contribute to the development and progression of CRC. Alternative splicing (AS) was found to be one of the molecular mechanisms underlying the development and progression of CRC. With the advent of genome/transcriptome sequencing and large patient databases, the broad role of aberrant AS in cancer development and progression has become clear. AS affects cancer initiation, proliferation, invasion, and migration. These splicing changes activate oncogenes or deactivate tumor suppressor genes by producing altered amounts of normally functional or new proteins with different, even opposing, functions. Thus, identifying and characterizing CRC-specific alternative splicing events and variants might help in designing new therapeutic splicing disrupter drugs. CRC-specific splicing events can be used as diagnostic and prognostic biomarkers. In this review, alternatively spliced events and their role in CRC development will be discussed. The paper also reviews recent research on alternatively spliced events that might be exploited as prognostic, diagnostic, and targeted therapeutic indicators. Of particular interest is the targeting of protein arginine methyltransferase (PMRT) isoforms for the development of new treatments and diagnostic tools. The potential challenges and limitations in translating these discoveries into clinical practice will also be addressed. Full article

(This article belongs to the Special Issue Contemporary Treatment of Colorectal Cancer)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Contemporary Treatment of Colorectal Cancer"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI